Green Tea Phenolic Epicatechins Inhibit Hepatitis C Virus Replication via Cycloxygenase-2 and Attenuate Virus-Induced Inflammation

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Lin, Ying Ting ^a   Wu, Yu Hsuan ^a   Tseng, Chin Kai ^a   Lin, Chun Kuang ^a   Chen, Wei Chun ^a   Hsu, Yao Chin ^b   Lee, Jin Ching ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2' METHYLCYTIDINE; ALPHA INTERFERON; CYCLOOXYGENASE 2; EPICATECHIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NONSTRUCTURAL PROTEIN 5A; TELAPREVIR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; EPIMER; GENE INACTIVATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCIBLE NITRIC OXIDE SYNTHASE GENE; INTERLEUKIN 1 BETA GENE; NONSTRUCTURAL PROTEIN 5A GENE; PROTEIN EXPRESSION; REPLICON; TUMOR NECROSIS FACTOR ALPHA GENE; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CATECHIN; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DEOXYCYTIDINE; GENE EXPRESSION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION; INTERFERON-ALPHA; INTERLEUKIN-1BETA; NITRIC OXIDE SYNTHASE TYPE II; OLIGOPEPTIDES; RNA, VIRAL; STEREOISOMERISM; TEA; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84872831778     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054466     Document Type: Article

References (55)

1. Alter MJ, (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol 13: 2436-2441.
2. Levrero M, (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25: 3834-3847.
3. Schaefer M, Mauss S, (2008) Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev 1: 177-187.
4. Salloum S, Tai AW, (2012) Treating hepatitis C infection by targeting the host. Transl Res 159: 421-429.
5. Lindenbach BD, Rice CM, (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436: 933-938.
6. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM, (2004) Structural biology of hepatitis C virus. Hepatology 39: 5-19.
7. Trujillo-Murillo K, Alvarez-Martinez O, Garza-Rodriguez L, Martinez-Rodriguez H, Bosques-Padilla F, et al. (2007) Additive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activity. J Viral Hepat 14: 608-617.
8. Nunez O, Fernandez-Martinez A, Majano PL, Apolinario A, Gomez-Gonzalo M, et al. (2004) Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 53: 1665-1672.
9. Morinaga S, Tarao K, Yamamoto Y, Nakamura Y, Rino Y, et al. (2007) Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma. J Gastroenterol Hepatol 22: 1249-1255.
10. Gee J, Lee IL, Grossman HB, Sabichi AL, (2008) Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells. Urol Oncol 26: 641-645.
11. Dong-rui M, Dong-hong Y, Hua-hong X, Jie L, (2010) [Relationship between cyclooxysenase 2 and serious hepatitis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 26: 914-915.
12. Lee JC, Chen WC, Wu SF, Tseng CK, Chiou CY, et al. (2011) Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2. Antiviral Res 89: 35-42.
13. Gretton S, Hughes M, Harris M, (2010) Hepatitis C virus RNA replication is regulated by Ras-Erk signalling. J Gen Virol 91: 671-680.
14. Okamoto M, Sakai M, Goto Y, Salim MT, Baba C, et al. (2009) Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560. Antivir Chem Chemother 20: 47-54.
15. Trujillo-Murillo K, Rincon-Sanchez AR, Martinez-Rodriguez H, Bosques-Padilla F, Ramos-Jimenez J, et al. (2008) Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 47: 1462-1472.
16. Friedman M, (2007) Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. Mol Nutr Food Res 51: 116-134.
17. Weber JM, Ruzindana-Umunyana A, Imbeault L, Sircar S, (2003) Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res 58: 167-173.
18. Chang LK, Wei TT, Chiu YF, Tung CP, Chuang JY, et al. (2003) Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate. Biochem Biophys Res Commun 301: 1062-1068.
19. Song JM, Lee KH, Seong BL, (2005) Antiviral effect of catechins in green tea on influenza virus. Antiviral Res 68: 66-74.
20. Li J, Zhou L, Zhang Y, (2001) [Studies on the effects of tea catechins against hepatitis B virus infection]. Zhonghua Yu Fang Yi Xue Za Zhi 35: 404-407.
21. Hamza A, Zhan CG, (2006) How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. J Phys Chem B Condens Matter Mater Surf Interfaces Biophys 110: 2910-2917.
22. Isaacs CE, Xu W, Merz G, Hillier S, Rohan L, et al. (2011) Digallate dimers of (-)-epigallocatechin gallate inactivate herpes simplex virus. Antimicrob Agents Chemother 55: 5646-5653.
23. Ho HY, Cheng ML, Weng SF, Leu YL, Chiu DT, (2009) Antiviral effect of epigallocatechin gallate on enterovirus 71. J Agric Food Chem 57: 6140-6147.
24. Ciesek S, von Hahn T, Colpitts CC, Schang LM, Friesland M, et al. (2011) The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 54: 1947-1955.
25. Chen C, Qiu H, Gong J, Liu Q, Xiao H, et al. (2012) (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. Arch Virol.
26. Zuo G, Li Z, Chen L, Xu X, (2007) Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res 76: 86-92.
27. Roh C, Jo SK, (2011) (-)-Epigallocatechin gallate inhibits hepatitis C virus (HCV) viral protein NS5B. Talanta 85: 2639-2642.
28. Blight KJ, Kolykhalov AA, Rice CM, (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290: 1972-1974.
29. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, et al. (2006) Cell culture and infection system for hepatitis C virus. Nat Protoc 1: 2334-2339.
30. Lee JC, Tseng CK, Wu SF, Chang FR, Chiu CC, et al. (2011) San-Huang-Xie-Xin-Tang extract suppresses hepatitis C virus replication and virus-induced cyclooxygenase-2 expression. Journal of Viral Hepatitis 18: E315-E324.
31. Corbeil CR, Englebienne P, Yannopoulos CG, Chan L, Das SK, et al. (2008) Docking ligands into flexible and solvated macromolecules. 2. Development and application of fitted 1.5 to the virtual screening of potential HCV polymerase inhibitors. J Chem Inf Model 48: 902-909.
32. Sakaki M, Makino R, Hiroishi K, Ueda K, Eguchi J, et al. (2010) Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression. Hepatol Res 40: 1219-1226.
33. Hou DX, Masuzaki S, Hashimoto F, Uto T, Tanigawa S, et al. (2007) Green tea proanthocyanidins inhibit cyclooxygenase-2 expression in LPS-activated mouse macrophages: molecular mechanisms and structure-activity relationship. Arch Biochem Biophys 460: 67-74.
34. Tazawa R, Xu XM, Wu KK, Wang LH, (1994) Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 203: 190-199.
35. Jesudian AB, Gambarin-Gelwan M, Jacobson IM, (2012) Advances in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N Y) 8: 91-101.
36. Bassit L, Grier J, Bennett M, Schinazi RF, (2008) Combinations of 2′-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir Chem Chemother 19: 25-31.
37. Jiang YF, He B, Li NP, Ma J, Gong GZ, et al. (2011) The oncogenic role of NS5A of hepatitis C virus is mediated by up-regulation of survivin gene expression in the hepatocellular cell through p53 and NF-kappaB pathways. Cell Biol Int 35: 1225-1232.
38. Park CM, Youn HJ, Chang HK, Song YS, (2010) TOP1 and 2, polysaccharides from Taraxacum officinale, attenuate CCl(4)-induced hepatic damage through the modulation of NF-kappaB and its regulatory mediators. Food Chem Toxicol 48: 1255-1261.
39. Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, et al. (2007) Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 55: 483-496.
40. Matthews CM, (2010) Steep your genes in health: drink tea. Proc (Bayl Univ Med Cent) 23: 142-144.
41. Takeshita M, Ishida Y, Akamatsu E, Ohmori Y, Sudoh M, et al. (2009) Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem 284: 21165-21176.
42. Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, et al. (2012) (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55: 720-729.
43. Li S, Kodama EN, Inoue Y, Tani H, Matsuura Y, et al. (2010) Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication. Antivir Chem Chemother 20: 239-248.
44. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM, (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 Suppl 1: S88-100.
45. Halfon P, Sarrazin C, (2012) Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 32 Suppl 1: 79-87.
46. Wohlfarth C, Efferth T, (2009) Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacol Sin 30: 25-30.
47. Lee JC, Tseng CK, Chen KJ, Huang KJ, Lin CK, et al. (2010) A cell-based reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA polymerase. Anal Biochem 403: 52-62.
48. Lee JC, Shih YF, Hsu SP, Chang TY, Chen LH, et al. (2003) Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal Biochem 316: 162-170.
49. Pan KL, Lee JC, Sung HW, Chang TY, Hsu JT, (2009) Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection. Antimicrob Agents Chemother 53: 4825-4834.
50. Tseng CK, Chen KJ, Lin CK, Hsu SH, Lee JC, (2011) An in vitro coupled transcription/translation reporter system for hepatitis C virus RNA-dependent RNA polymerase. Anal Biochem 418: 50-57.
51. Ikeda M, Kato N, (2007) Modulation of host metabolism as a target of new antivirals. Adv Drug Deliv Rev 59: 1277-1289.
52. Wu KM, Dou J, Ghantous H, Chen S, Bigger A, et al. (2010) Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A. Regul Toxicol Pharmacol 56: 1-3.
53. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, et al. (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66: 1234-1240.
54. Laurie SA, Miller VA, Grant SC, Kris MG, Ng KK, (2005) Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol 55: 33-38.
55. Shanafelt TD, Call TG, Zent CS, Leis JF, Laplant B, et al. (2012) Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer.